Xortx Therapeutics Inc(XRTX-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low3.030
Day High3.050
Open:3.050
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
GlobeNewswire
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
GlobeNewswire
XORTX Announces Closing of US$5 Million Public Offering
GlobeNewswire
XORTX Announces US$5 Million Public Offering
GlobeNewswire
XORTX Meets Nasdaq Continued Listing Requirements
GlobeNewswire
XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset
GlobeNewswire
XORTX Confirms Effective Date of Share Consolidation
GlobeNewswire
XORTX Announces Results of Annual and Special Meeting of Shareholders
GlobeNewswire
XORTX Announces Change of Effective Date of Share Consolidation
GlobeNewswire
XORTX Announces Share Consolidation
GlobeNewswire
XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting
GlobeNewswire
XORTX Announces Substitute Director Nominees for its Upcoming Annual and Special Meeting of Shareholders
GlobeNewswire
XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation
GlobeNewswire
XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders
Newsfile
Upcoming Meeting Dates - February 9, 2026
GlobeNewswire
XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
GlobeNewswire
XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update
GlobeNewswire
XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
GlobeNewswire
XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

Profile

XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.